» Articles » PMID: 25420671

Octamer-binding Protein 4 Affects the Cell Biology and Phenotypic Transition of Lung Cancer Cells Involving β-catenin/E-cadherin Complex Degradation

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2014 Nov 26
PMID 25420671
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical studies have reported evidence for the involvement of octamer‑binding protein 4 (Oct4) in the tumorigenicity and progression of lung cancer; however, the role of Oct4 in lung cancer cell biology in vitro and its mechanism of action remain to be elucidated. Mortality among lung cancer patients is more frequently due to metastasis rather than their primary tumors. Epithelial‑mesenchymal transition (EMT) is a prominent biological event for the induction of epithelial cancer metastasis. The aim of the present study was to investigate whether Oct4 had the capacity to induce lung cancer cell metastasis via the promoting the EMT in vitro. Moreover, the effect of Oct4 on the β‑catenin/E‑cadherin complex, associated with EMT, was examined using immunofluorescence and immunoprecipitation assays as well as western blot analysis. The results demonstrated that Oct4 enhanced cell invasion and adhesion accompanied by the downregulation of epithelial marker cytokeratin, and upregulation of the mesenchymal markers vimentin and N‑cadherin. Furthermore, Oct4 induced EMT of lung cancer cells by promoting β‑catenin/E‑cadherin complex degradation and regulating nuclear localization of β‑catenin. In conclusion, the present study indicated that Oct4 affected the cell biology of lung cancer cells in vitro through promoting lung cancer cell metastasis via EMT; in addition, the results suggested that the association and degradation of the β‑catenin/E‑cadherin complex was regulated by Oct4 during the process of EMT.

Citing Articles

Cancer stem cell-immune cell crosstalk in breast tumor microenvironment: a determinant of therapeutic facet.

Guha A, Goswami K, Sultana J, Ganguly N, Choudhury P, Chakravarti M Front Immunol. 2023; 14:1245421.

PMID: 38090567 PMC: 10711058. DOI: 10.3389/fimmu.2023.1245421.


OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2 breast cancer patients.

Yang F, Zhang J, Yang H Onco Targets Ther. 2018; 11:7873-7881.

PMID: 30464534 PMC: 6228048. DOI: 10.2147/OTT.S173522.


Shikonin induces mitochondria-mediated apoptosis and attenuates epithelial-mesenchymal transition in cisplatin-resistant human ovarian cancer cells.

Shilnikova K, Piao M, Kang K, Ryu Y, Park J, Hyun Y Oncol Lett. 2018; 15(4):5417-5424.

PMID: 29563994 PMC: 5858079. DOI: 10.3892/ol.2018.8065.


Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.

Gwak J, Kim M, Kim H, Jang M, Park S Oncotarget. 2017; 8(22):36305-36318.

PMID: 28422735 PMC: 5482656. DOI: 10.18632/oncotarget.16750.


Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347.

Fan H, Liu G, Zhao C, Li X, Yang X Oncol Lett. 2017; 13(1):396-402.

PMID: 28123573 PMC: 5244871. DOI: 10.3892/ol.2016.5400.